Skip to Main Content

Author Details

Antonio Nieto
Clinical R&D
2008
30
20
Kirsten Obernier (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36252599Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial.Lancet Respir Med2023
37634282Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid Tumours.Eur J Cancer2023
35012962Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19.Life Sci Alliance2022
34075384Plitidepsin has a positive therapeutic index in adult patients with COVID-19 requiring hospitalization.medRxiv2021
34521554Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL).Gynecol Oncol2021
28467918Higher antitumor activity of trabectedin in germline BRCA2 carriers with advanced breast cancer as compared to BRCA1 carriers: A subset analysis of a dedicated phase II trial.Breast2017
26749361A phase II trial of trabectedin in triple-negative and HER2-overexpressing metastatic breast cancer.Breast Cancer Res Treat2016
25722380Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study.Ann Oncol2015
26108247Trabectedin plus pegylated liposomal doxorubicin: retrospective analysis in heavily pretreated platinum-sensitive ovarian cancer.Tumori2015
23987833Efficacy and safety of trabectedin as an early treatment for advanced or metastatic liposarcoma and leiomyosarcoma.Future Oncol2014
24512981Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas.Eur J Cancer2014
24692579Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: results of an international first-in-class phase II study.Ann Oncol2014
24211400Nibrin is a marker of clinical outcome in patients with advanced serous ovarian cancer treated in the phase III OVA-301 trial.Gynecol Oncol2014
23117071Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy.Ann Oncol2013
24022187Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials.Br J Cancer2013
23364677Analysis of DNA repair-related genes in breast cancer reveals CUL4A ubiquitin ligase as a novel biomarker of trabectedin response.Mol Cancer Ther2013
20960029Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone.Invest New Drugs2012
22765965Patient-reported outcomes in relapsed ovarian cancer: results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone.Gynecol Oncol2012
22749255A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas.Eur J Cancer2012
22484722A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin.Cancer Chemother Pharmacol2012
22197612Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum.Lung Cancer2012
21930687Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer.Ann Oncol2012
21642514Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma.Ann Oncol2012
21484250A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials.Invest New Drugs2012
20643863Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval.Ann Oncol2011
21376569Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study.Eur J Cancer2011
21287534ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma.Cancer2011
21416137Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis.Cancer Chemother Pharmacol2011
20406837Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors.Clin Cancer Res2010
18281545Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors.Clin Cancer Res2008
  • 1 - 30 of 30

Recommended Authors

George Au-Yeung
The University of Melbourne
Career Start Year 2012
Number of shared co-authors 0
Bo Gao
Crown Princess Mary Cancer Centre, Westmead Hospital
Career Start Year 2008
Number of shared co-authors 6
Gideon M Blumenthal
Oncology Center of Excellence
Career Start Year 2008
Number of shared co-authors 0
Saskia Liti??re
Center for Statistics, Hasselt University
Career Start Year 2007
Number of shared co-authors 1
Stephen Welch
Victoria Hospital
Career Start Year 2007
Number of shared co-authors 1
Julia A Beaver
Center for Drug Evaluation and Research
Career Start Year 2007
Number of shared co-authors 0
Liz-Anne Lewsley
CRUK Clinical Trials Unit, University of Glasgow
Career Start Year 2006
Number of shared co-authors 5
Paul Hamberg
Franciscus Gasthuis & Vlietland Hospital Rotterdam and Schiedam
Career Start Year 2006
Number of shared co-authors 0
Joseph A Ludwig
The University of Texas MD Anderson Cancer Center
Career Start Year 2005
Number of shared co-authors 1
Shubham Pant
The University of Texas MD Anderson Cancer Center
Career Start Year 2005
Number of shared co-authors 1
Susana Banerjee
The Royal Marsden NHS Foundation Trust and Institute of Cancer Research
Career Start Year 2005
Number of shared co-authors 5
Neeltje Steeghs
Netherlands Cancer Institute-Antoni Van Leeuwenhoek
Career Start Year 2003
Number of shared co-authors 0
Sandra J Strauss
University College London, Cancer Institute
Career Start Year 2003
Number of shared co-authors 0
Philippe L Bedard
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2002
Number of shared co-authors 1
Eleni Andreopoulou
New York Presbyterian Hospital
Career Start Year 1997
Number of shared co-authors 0
Sunil Sharma
Brody School of Medicine, East Carolina University
Career Start Year 1997
Number of shared co-authors 0
Antonio Cubillo
Hospital HM Universitario Sanchinarro
Career Start Year 1997
Number of shared co-authors 1
Primo N Lara
University of California Davis Comprehensive Cancer Center
Career Start Year 1996
Number of shared co-authors 1
Paul Haluska
Mayo Clinic
Career Start Year 1996
Number of shared co-authors 5
Lillian L Siu
Princess Margaret Cancer Centre, University Ave
Career Start Year 1995
Number of shared co-authors 2
Stefan Sleijfer
Erasmus MC Cancer Institute, University Medical Center Rotterdam
Career Start Year 1994
Number of shared co-authors 1
Joan Albanell
Hospital del Mar Research Institute
Career Start Year 1990
Number of shared co-authors 3
Suresh Nair
Lehigh Valley Topper Cancer Institute
Career Start Year 1990
Number of shared co-authors 0
Emile E Voest
The Netherlands Cancer Institute
Career Start Year 1989
Number of shared co-authors 0
Jan H M Schellens
Department of Pharmaceutical Sciences, Utrecht University
Career Start Year 1987
Number of shared co-authors 7
Chris Twelves
Leeds Teaching Hospitals NHS Trust, University of Leeds
Career Start Year 1986
Number of shared co-authors 2
Mark J Ratain
University of Chicago
Career Start Year 1985
Number of shared co-authors 0
James H Doroshow
National Cancer Institute, National Institutes of Health
Career Start Year 1974
Number of shared co-authors 1
Antonio Jimeno
University of Colorado School of Medicine
Career Start Year 1974
Number of shared co-authors 3
Ronald de Wit
Erasmus MC Cancer Institute
Career Start Year 1972
Number of shared co-authors 0

Collaborators

Javier G??mez
Hospital Universitario Marques de Valdecilla
Co-authored papers 6
Jos?? Jimeno
Promontory Therapeutics Inc.
Co-authored papers 5
Bonaventura Clotet
IrsiCaixa AIDS Research Institute, Hospital Universitari Germans Trias i Pujol
Co-authored papers 2
Noemi Cabello
Centro Sandoval and Hospital Universitario Clinico de San Carlos
Co-authored papers 2
Jos?? Barber??n
Hospital Universitario HM Monteprincipe, HM Hospitales
Co-authored papers 2
Greg J Towers
University College London
Co-authored papers 2
Beatriz de Rivas
University of the Basque Country UPV/EHU
Co-authored papers 2
Pablo Avil??s
Departamento de Toxicologia y Farmacologia Preclinica
Co-authored papers 2
Rubin Lubomirov
Clinical Development
Co-authored papers 2
Kirsten Obernier (CM4AI)
University of California San Francisco
Co-authored papers 2
Nuria Izquierdo-Useros
IrsiCaixa AIDS Research Institute, Hospital Universitari Germans Trias i Pujol
Co-authored papers 2
Jose F Varona
Hospital Universitario HM Monteprincipe, HM Hospitales
Co-authored papers 2
Jordi Rodon
The University of Texas MD Anderson Cancer Center
Co-authored papers 2
Salvador Fudio
Clinical Development
Co-authored papers 2
Soner Yildiz
University of Geneva
Co-authored papers 2
Julio Ancochea
Instituto de Salud Carlos III, Hospital Universitario La Princesa
Co-authored papers 2
Sonia Zu??iga
Campus Universidad Autonoma de Madrid
Co-authored papers 2
Roger Paredes
Hospital Germans Trias i Pujol
Co-authored papers 2
Daniel Carnevali-Ruiz
Hospital Universitario Quironsalud Madrid
Co-authored papers 2
Jes??s Fort??n
Hospital Universitario Ramon y Cajal
Co-authored papers 2
Kris M White
Quantitative Biosciences Institute (QBI) Coronavirus Research Group (QCRG)
Co-authored papers 2
Alfonso Monereo
Hospital Universitario de Getafe
Co-authored papers 2
Maria J S L Pontes
Co-authored papers 2
Pedro Landete
Hospital Universitario de La Princesa
Co-authored papers 2
Daniel Abad
Universidad Europea
Co-authored papers 2
Isabelle Ray-Coquard
University Claude Bernard Lyon I
Co-authored papers 2
Nevan J Krogan (CM4AI)
University of California San Francisco
Co-authored papers 2
Lucy Thorne
University College London
Co-authored papers 2
Roberto Vates
Hospital Universitario de Getafe
Co-authored papers 2
Luis Enjuanes
Campus Universidad Autonoma de Madrid
Co-authored papers 2
Release 1.2